Cytosorbents | 8-K: CytoSorbents Reports Third Quarter 2022 Financial and Operational Results CytoSorbents expects to achieve first milestone of the U.S. pivotal STAR-T Trial this month
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.